CZECANCA: CZEch CAncer paNel for Clinical Application – Design and Optimization of the Targeted Sequencing Panel for the Identification of Cancer Susceptibility in High-risk Individuals from the Czech Republic

Česká verzia

Authors: J. Soukupová ¹; P. Zemánková ¹; P. Kleiblová ^1,2; M. Janatová ¹; Z. Kleibl ¹
Authors place of work: Ústav biochemie a experimentální onkologie, 1. LF UK v Praze ¹; Ústav biologie a lékařské genetiky, 1. LF UK a VFN v Praze ²
Published in the journal: Klin Onkol 2016; 29(Supplementum 1): 46-54
Category: Original Articles
doi: https://doi.org/10.14735/amko2016S46

Summary

Individuals with hereditary cancer syndromes form a minor but clinically important subgroup of oncology patients, comprising several thousand cases in the Czech Republic annually. In these patients, the identification of pathogenic mutations in cancer susceptibility genes has an important predictive and, in some cases, prognostic value. It also enables rational preventive strategies in asymptomatic carriers from affected families. More than 150 cancer susceptibility genes have been described so far; however, mutations in most of them are very rare, occurring with substantial population variability, and hence their clinical interpretation is very complicated. Diagnostics of mutations in cancer susceptibility genes have benefited from the broad availability of next-generation sequencing analyses using targeted gene panels. In order to rationalize the diagnostics of hereditary cancer syndromes in the Czech Republic, we have prepared the sequence capture panel “CZECANCA”, targeting 219 cancer susceptibility genes. Besides more than 50 clinically important high- and moderate-penetrance susceptibility genes, the panel also targets less common candidate genes with uncertain clinical relevance. Alongside the panel design, we have optimized the analytical and bioinformatics pipeline, which will facilitate establishing a collective nationwide database of genotypes and clinical data from the analyzed individuals. The key objective of this project is to provide diagnostic laboratories in the Czech Republic with a reliable procedure and collective database improving the clinical utility of next-generation sequencing analyses in high-risk patients, which would help improve the interpretation of rare or population-specific variants in cancer susceptibility genes.

Key words:
genetic predisposition testing – hereditary cancer syndromes – high-throughput nucleotide sequencing – genetic information databases – panel sequencing – sequence capture – next-generation sequencing (NGS)

This work was supported by Czech Ministry of Health grants No. NT14054, NV15-28830A, NV15--27695A and The League Against Cancer Prague.

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE recommendation for biomedical papers.

Submitted:
2. 10. 2015

Accepted:
13. 10. 2015

Zdroje

1. Foretova L, Petrakova K, Palacova M et al. Genetic testing and prevention of hereditary cancer at the MMCI – over 10 years of experience. Klin Onkol 2010; 23(6): 388– 400.

2. Rahman N. Realizing the promise of cancer predisposition genes. Nature 2014; 505(7483): 302– 308. doi: 10.1038/ nature12981.

3. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature 2009; 458(7239): 719– 724. doi: 10.1038/ nature07943.

4. Stratton MR, Rahman N. The emerging landscape of breast cancer susceptibility. Nat Genet 2008; 40(1): 17– 22.

5. Saam J, Arnell C, Theisen A et al. Patients tested at a laboratory for hereditary cancer syndromes show an overlap for multiple syndromes in their personal and familial cancer histories. Oncology 2015; 89(5): 288– 293. doi: 10.1159/ 000437307.

6. Kleibl Z, Novotny J, Bezdickova D et al. The CHEK2 c.1100delC germline mutation rarely contributes to breast cancer development in the Czech Republic. Breast Cancer Res Treat 2005; 90(2): 165– 167.

7. Schroeder C, Faust U, Sturm M et al. HBOC multi-gene panel testing: comparison of two sequencing centers. Breast Cancer Res Treat 2015; 152(1): 129– 136. doi: 10.1007/ s10549-015-3429-9.

8. Lhota F, Stranecky V, Boudova P et al. Targeted next-gen sequencing in high-risk BRCA1- and BRCA2-negative breast cancer patients. Curr Oncol 2014; 21(2): e376.

9. Kluska A, Balabas A, Paziewska A et al. New recurrent BRCA1/ 2 mutations in Polish patients with familial breast/ ovarian cancer detected by next generation sequencing. BMC Med Genomics 2015; 8: 19. doi: 10.1186/ s12920-015-0092-2.

10. Cybulski C, Lubiński J, Wokołorczyk D et al. Mutations predisposing to breast cancer in 12 candidate genes in breast cancer patients from Poland. Clin Genet 2014; 88(4): 366– 370. doi: 10.1111/ cge.12524.

11. Sims D, Sudbery I, Ilott NE et al. Sequencing depth and coverage: key considerations in genomic analyses. Nat Rev Genet 2014; 15(2): 121– 132. doi: 10.1038/ nrg3642.